Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal VG2025 in Advanced Solid Tumors With Carcinomatosis
NCT06365918Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VG2025 in solid tumor (advanced stage) and peritoneal carcinomatosis (PC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events (AEs), Maximum Tolerated Dose and 1 more. Planned start Sep 2024; status: withdrawn.
02
Drugs
VG2025
03
Conditions
solid tumor (advanced stage)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT06365918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365918.